Month: March 2022

GUILFORD, Conn., March 23, 2022 (GLOBE NEWSWIRE) — Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™, today announced fourth quarter and full year 2021 financial results and provided a business update. “2021 was an incredible year at Hyperfine. We accelerated our Swoop launch by installing 23 commercial systems and over 50 total systems*, secured an experienced management team and Board of Directors, raised over $160 million in gross proceeds from our business combination, transitioned to a public company, and created several new opportunities for research at top clinical institutions while expanding our sales presence around the globe,” said Dave Scott, Chief Executive Officer and President of Hyperfine. “We look forward to continued...

— Record Earnings Driven by Excellent Execution and Continued Strength in Direct to Consumer — — Fiscal 2022 Earnings Per Share Projected to Range from $8.75 to $9.15 — — Increases Quarterly Dividend 31% to $0.55 per Share — ATLANTA, March 23, 2022 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2021 ended January 29, 2022. Due to the material impact of COVID-19 on the Company’s business in fiscal 2020, this release includes comparisons of fiscal 2021 results to both fiscal 2020 and fiscal 2019. Full fiscal 2021 consolidated net sales increased to $1.142 billion compared to $749 million in fiscal 2020 and $1.123 billion in fiscal 2019. Sales of Lanier Apparel, which the Company exited in the third quarter of fiscal...

Fourth quarter results:Orders grew 27% and revenue increased 11% compared to prior year, with broad-based growth across all segments Significant inflationary pressures and supply chain disruptions continued to impact operating resultsOutlook:First quarter guidance reflects significant revenue growth over prior year and continuation of supply chain disruptions and inflationary pressures Company targets strong revenue and earnings growth in fiscal 2023 driven by expected benefits of pricing actions and anticipated stronger demand from companies transforming their offices to support hybrid and in-person workGRAND RAPIDS, Mich., March 23, 2022 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) today reported fourth quarter revenue of $753.1 million and a net loss of $2.2 million, or $0.02 per share. In the prior year, Steelcase...

Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M initial public offering and $31.25M private placement PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced financial results for the year ended December 31, 2021, and highlighted recent corporate accomplishments. “Context has bolstered our corporate, financial, and scientific efforts over the past two quarters. We’ve grown our R&D and operations teams, reported positive data on lead product candidate onapristone extended release (“ONA-XR”) in early breast cancer, and closed on...

– Entered into landmark collaboration with GSK for EOS-448/GSK4428859A; began dosing patients in Jemperli (dostarlimab-gxly) and EOS-448 combination trial and announced plans to initiate multiple registration-directed clinical trials with this combination – Initiating trials combining EOS-448 and Jemperli in triplet regimens with inupadenant and GSK’s investigational anti-CD96 antibody, GSK6097608 – Advanced clinical development of inupadenant, EOS-850, an A2Areceptor antagonist, start of expansion studies in PD-1 resistant melanoma in combination with pembrolizumab as well as a study further exploring novel predictive biomarkers – Cash balance of $848.5MM as of December 31, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupadenant and growing pipeline of preclinical...

Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million in net proceeds Dosed first patient in Phase 3 clinical program evaluating DFD-29 for the treatment of papulopustular rosacea Company to hold conference call on March 23, 2022 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 23, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2021. Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer,...